Neelu Atwal - Biosyent Director Resources

All Insiders . Canada . 
Stock . Biosyent . Stakeholders . Insider . Neelu Atwal
RX Stock  CAD 11.09  0.01  0.09%   

Director

Neelu Atwal is Director Resources of Biosyent
Phone905 206 0013
Webhttps://www.biosyent.com

Biosyent Management Efficiency

The company has return on total asset (ROA) of 0.1286 % which means that it generated a profit of $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2088 %, meaning that it created $0.2088 on every $100 dollars invested by stockholders. Biosyent's management efficiency ratios could be used to measure how well Biosyent manages its routine affairs as well as how well it operates its assets and liabilities.
Biosyent currently holds 1.22 M in liabilities. Biosyent has a current ratio of 9.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biosyent until it has trouble settling it off, either with new capital or with free cash flow. So, Biosyent's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biosyent sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biosyent to invest in growth at high rates of return. When we think about Biosyent's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Joseph CordianoCovalon Technologies
N/A
Murray MillerCovalon Technologies
N/A
Gale PollockCovalon Technologies
N/A
Meir JakobsohnKnight Therapeutics
N/A
Ronald SmithCovalon Technologies
68
Ian BrindleCovalon Technologies
N/A
Emilio PrestiCipher Pharmaceuticals
N/A
Robert LandeKnight Therapeutics
53
John SukCovalon Technologies
N/A
Jeffrey MandelCovalon Technologies
N/A
Myrna FrancisCovalon Technologies
N/A
Sylvie TendlerKnight Therapeutics
N/A
Nancy HarrisonKnight Therapeutics
N/A
John HandsCovalon Technologies
N/A
Jody EngelKnight Therapeutics
N/A
Elinor CaplanCovalon Technologies
N/A
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BIOSYENT INC operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on TSX Venture Exchange. Biosyent (RX) is traded on TSX Venture Exchange in Canada and employs 5 people.

Management Performance

Return On Equity0.21
Return On Asset0.13

Biosyent Leadership Team

Elected by the shareholders, the Biosyent's board of directors comprises two types of representatives: Biosyent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biosyent. The board's role is to monitor Biosyent's management team and ensure that shareholders' interests are well served. Biosyent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biosyent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alfred DSouza, Advisor
Neelu Atwal, Director Resources
Ren Goehrum, CEO Chairman
Robert March, CFO, Senior Vice President - Finance
Joost Mark, Vice Development

Biosyent Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biosyent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Number Of Shares Shorted357

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Biosyent Stock Analysis

When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY